Inconsistency in large pharmacogenomic studies

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

Gene Ontology: tool for the unification of biology

Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

The proof and measurement of association between two things.

Spearman, C. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyq191 · Cited by 7,777

The kappa statistic in reliability studies: use, interpretation, and sample size requirements

Sim, J., & Wright, C. C. (2005) · Physical Therapy · doi:10.1093/ptj/85.3.257 · Cited by 4,093

The NCI60 human tumour cell line anticancer drug screen

Shoemaker, R. H. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1951 · Cited by 2,673

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456

ArrayExpress--a public database of microarray experiments and gene expression profiles

Parkinson, H., Kapushesky, M., Shojatalab, M., Abeygunawardena, N., Coulson, R., Farne, A., Holloway, E., Kolesnykov, N., Lilja, P., Lukk, M., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl995 · Cited by 754

Frozen robust multiarray analysis (fRMA)

McCall, M. N., Bolstad, B. M., & Irizarry, R. A. (2010) · Biostatistics · doi:10.1093/biostatistics/kxp059 · Cited by 594

Subtype and pathway specific responses to anticancer compounds in breast cancer

Heiser, L. M., Sadanandam, A., Kuo, W., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F. K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018854108 · Cited by 464

Spatial artifact detection improves the reproducibility of drug screening experiments

Ianevski, A., Nader, K. M., Potdar, S., Gorbonos, A., Ianevski, F., Tanoli, Z., Saarela, J., & Aittokallio, T. A. (2025) · iScience · doi:10.1016/j.isci.2025.113470 · Cited by 1

A multi-center study on the consistency of drug sensitivity testing in patients with acute myeloid leukemia

Willoch, K., Zhao, Z., Durán, P. A., Mikaeloff, F., Struyf, N., Österroos, A., Lehmann, S., Kallioniemi, O., Saarela, J., Tyner, J. W., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01480-4 · Cited by 1

Dry computational approaches for wet medical problems

Emmert‐Streib, F., Zhang, S., & Hamilton, P. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-26 · Cited by 1

PROGNOSTICATE THE DRUGS FOR MULTIPLE MYELOMA PATIENTS BY USING GENE EXPRESSION TECHNIQUE WITH POLYCLONAL AND MONOCLONAL SAMPLES

Hemalatha, R. J., & Devi, T. P. A. (2018) · ICTACT Journal on Image and Video Processing · doi:10.21917/ijivp.2017.0235 · Cited by 1

Computational Intelligence-Based Cheminformatics Model as Cancer Therapeutics

Biswas, R., Dey, A., Puri, R., Akermi, S., Sahoo, S., Panesar, R., Jana, C., Jayant, S., Nigam, A., Bernard, J., et al. (2022) · Studies in computational intelligence · doi:10.1007/978-981-16-9221-5_15 · Cited by 1

The IC-50-time evolution is a new model to improve drug responses consistency of large scale studies

Alileche, A. (2022) · F1000Research · doi:10.12688/f1000research.108673.1 · Cited by 1

Utilizing temporal variations in chemotherapeutic response to improve breast cancer treatment efficacy

McGrail, D. J., Patel, K. S., Khambhati, N. N., Pithadia, K. J., & Dawson, M. (2015) · AIMS bioengineering · doi:10.3934/bioeng.2015.4.310 · Cited by 1

Integrative and interdisciplinary challenges in translational bioinformatics

Ma, T. (2014) · ACM SIGBioinformatics Record · doi:10.1145/2661732.2661733 · Cited by 1

Do We Need a Science of Science?

Maiväli, Ü. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418689-7.00001-6 · Cited by 1

Consistency of in vitro drug sensitivities within pharmacological classes

Hon, C. S.-Y., Nair, S. K., Smirnov, P., Sharifi-Noghabi, H., Feizi, N., Shepherd, S., & Haibe‐Kains, B. (2021) · Journal of Undergraduate Life Sciences · doi:10.33137/juls.v15i1.37046 · Cited by 1

Testing the Stability of Drug Resistance on Cryopreserved, Gene-Engineered Human Induced Pluripotent Stem Cells

Khan, D., Nickel, A., Jeising, S., Uhlmann, C., Muhammad, S., Hänggi, D., Fischer, I., & Kahlert, U. D. (2021) · Pharmaceuticals · doi:10.3390/ph14090919 · Cited by 1

In vitro to in vivo extrapolation for drug-induced liver injury using a pair ranking method_suppl

Liu, Z. (2017) · ALTEX · doi:10.14573/altex.1610201s · Cited by 1

Influence of cryopreservation on drug responses and gene expression of AML cells: Implications for the use of biobanked tissues

Meszaros, N., LIND, K., Sehlke, R., Vilagos, B., Krall, N., Vladimer, G. I., & Sill, H. (2022) · British Journal of Haematology · doi:10.1111/bjh.18557 · Cited by 1

Personalized cancer treatments suffer setback

Hayden, E. C. (2013) · Nature · doi:10.1038/nature.2013.14238 · Cited by 1

Translational Bioinformatics: Informatics, Medicine, and -Omics

Paraíso-Medina, S., Pérez-Rey, D., Alonso-Calvo, R., Munteanu, C. R., Pazos, A., Kulikowski, C. A., & Maojo, V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.10879-7 · Cited by 3

Chemical Systems Biology Studies of Triple Negative Breast Cancer Cell Lines

Gautam, P. (2017) · Työväentutkimus Vuosikirja · Cited by 1

INTEGRATIVE BIOINFORMATICS OF FUNCTIONAL AND GENOMIC PROFILES FOR CANCER SYSTEMS MEDICINE

Jaiswal, A. (2018) · Työväentutkimus Vuosikirja · Cited by 1

Editorial: Using Cells in Epidemiological Studies to Characterize Individual Response to Environmental Hazards

Il’yasova, D., & Kinev, A. V. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00284 · Cited by 1

A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimatesPreprint

Wang, D. Y. Q., Hensman, J., Kutkaite, G., Toh, T. S., GDSC Screening Team, Dry, J. R., Sáez-Rodríguez, J., Garnett, M. J., Menden, M. P., & Dondelinger, F. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.01.072983 · Cited by 1

Clinical Forecasting using Ex Vivo Drug Sensitivity Profiling of Acute Myeloid LeukemiaPreprint

Andersen, A. N., Brodersen, A. M., Durán, P. A., Piechaczyk, L., Tadele, D. S., Baken, L., Fredriksen, J., Stoksflod, M., Lenartova, A., Fløisand, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.11.509866 · Cited by 1

Meta-analysis of preclinical pharmacogenomic studies to discover robust and translatable biomarkers of drug responsePreprint

Smirnov, P., Nair, S. K., Aghababazadeh, F. A., Feizi, N., Smith, I., Pugh, T. J., & Haibe‐Kains, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.22.513279 · Cited by 1

Machine learning approaches for drug virtual screening

Playe, B. (2019) · theses.fr (ABES) · doi:10.70675/8bd92cdfzf773z462dzba58za5132a1d4e92 · Cited by 1

A new standard in reproducibility

Haas, M. J. (2014) · Science-Business eXchange · doi:10.1038/scibx.2014.76

Divergence in drug data between studies

Harrison, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4213

Implementation of Genomic Medicine: Tools and Challenges

Grech, G., van Schaik, R. H., & Borg, J. (2015) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-319-15344-5_12

Association analysis of the perturbation of interactions in biological pathways and anticancer drug activity

Lee, J., & Lee, D. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.009

Quantification of read species behavior within whole genome sequencing of cancer genomes for the stratification and visualization of genomic variation

Hibsh, D., Buetow, K. H., Yaari, G., & Efroni, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw031

Hopes raised for simplification of cancer research

Hayden, E. C. (2013) · Nature · doi:10.1038/nature.2013.14318

Computational Data Integration in Toxicogenomics

Constantinescu, S., Sturla, S. J., Marra, G., Wollscheid, B., & Beerenwinkel, N. (2015) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-2778-4_15

Strategies to overcome antineoplastic drug resistance

Cirkel, G. A. (2016) · Utrecht University Repository (Utrecht University)

A Gene Co-Expression Network Mining Approach for Differential Expression Analysis

Morgan, D. C. (2015) · OhioLink ETD Center (Ohio Library and Information Network)

Simulation of cancer cell line pharmacogenomics data to optimise experimental design and analysis strategyPreprint

Mistry, H. B., & Chapman, P. (2018) · doi:10.7287/peerj.preprints.27345v1

Computational methods for personalized cancer genomics

Hou, J. P. (2017) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)

Robust and clinically relevant prediction of response to anti-cancer drugs via network integration of molecular profilesPreprint

Franco, M., Jeggari, A., Peuget, S., Böttger, F., Selivanova, G., & Alexeyenko, A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/301838

Genomics and Proteomics in Neuro-Oncology

Cohen, A. L., & Colman, H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00005-x

Statistical Methods for Evaluation of Bioactivity of Chemicals Using Quantitative High Throughput Screening

Nemoto, A., & Ushijima, M. (2018) · Japanese Journal of Biometrics · doi:10.5691/jjb.38.93

Step II: Target Validation

Seneci, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-099420-8.00002-x

Karyotypic divergence confounds cellular phenotypes in large pharmacogenomic studiesPreprint

Quevedo, R., El-Hachem, N., Smirnov, P., Safikhani, Z., Pugh, T. J., & Haibe‐Kains, B. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/574350

PharmacoDB: an integrative database for mining in vitro drug screening studiesPreprint

Smirnov, P., Kofia, V., Maru, A., Freeman, M., Ho, C., El-Hachem, N., Adam, G.-A., Ba-Alawi, W., Safikhani, Z., & Haibe‐Kains, B. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/195149

Understanding Disease and Disease Relationships Using Transcriptomic Data

Oerton, E. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.36391

Overcoming Resistance in Patient-Derived Xenograft Models of BCR-ABL-Rearranged Acute Lymphoblastic Leukemia

Murakami, M. A. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

Applications of Microarray in Cancer Cell Signaling Pathways

Lui, P. L., Chung, T., & Chng, W. J. (2019) · Springer eBooks · doi:10.1007/978-981-32-9816-3_15

Challenges

Pal, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805274-7.00013-0

Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer

Kimble, D. C., Dvergsten, E., Thomeas, V., Karovic, S., Conrads, T. P., & Maitland, M. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.044

CellMinerCDB for Integrative Genomics and Pharmacogenomics Analyses of Cancer Cell LinesPreprint

Rajapakse, V. N., Luna, A., Yamade, M., Loman, L., Varma, S. R., Sunshine, M., Iorio, F., Sousa, F. G., Elloumi, F., Aladjem, M. I., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3192032

In vitro and in vivo evaluation of paclitaxel-induced release of apoptotic biomarker ccCK18 to guide treatment optimization in ovarian cancerPreprint

Thaye, E. D., de Vijver, K. K. V., Dorpe, J. V., Vermeulen, A., Bocxlaer, J. V., & Colin, P. J. (2020) · Research Square · doi:10.21203/rs.3.rs-61635/v2

Therapeutic applications of three-dimensional organoid models in lung cancer

Yeo, C. D., Yun, Y.-P., Ahn, D. H., Hwang, Y., Yang, S. H., Won, H., Cho, H. J., Park, C. K., Kim, S. J., & Park, J. Y. (2021) · Organoid · doi:10.51335/organoid.2021.1.e6

Computational-driven understanding of the regulatory mechanisms of the breast cancer transcriptome and its implications for drug treatment

Huang, S. (2021) · Mspace (University of Manitoba)

Faculty Opinions recommendation of Genetic and transcriptional evolution alters cancer cell line drug response.

Sáez-Rodríguez, J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733769287.793563721

Looking back at the first twenty years of genomics

Quackenbush, J. F. (2021) · Quantitative Biology · doi:10.15302/j-qb-021-0286

Faculty Opinions recommendation of Integrative Analysis of Hypoxia-Associated Signature in Pan-Cancer.

Chakrabarti, S. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738582898.793579467

Faculty Opinions recommendation of Next-generation characterization of the Cancer Cell Line Encyclopedia.

Chen, J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735709859.793560036

Simulation of cancer cell line pharmacogenomics data to optimise experimental design and analysis strategyPreprint

Mistry, H. B., & Chapman, P. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/174862

In Vitro and in Vivo Evaluation of Paclitaxel-induced Release of Apoptotic Biomarker ccCK18 to Guide Treatment Optimization in Ovarian CancerPreprint

Thaye, E. D., de Vijver, K. K. V., Dorpe, J. V., Vermeulen, A., Bocxlaer, J. V., & Colin, P. J. (2020) · Research Square · doi:10.21203/rs.3.rs-61635/v1

Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen

Hoffmann, J. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_148-1

Data from Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity

Ba-Alawi, W., Nair, S. K., Li, B., Mammoliti, A., Smirnov, P., Mer, A. S., Penn, L. Z., & Haibe‐Kains, B. (2023) · doi:10.1158/0008-5472.c.6514155.v1

Data from Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma

Li, C., Lin, W.-Y., Rizvi, H. A., Cai, H., McFarland, C. D., Rogers, Z. N., Yousefi, M., Winters, I. P., Rudin, C. M., Petrov, D. A., et al. (2023) · doi:10.1158/0008-5472.c.6513663

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

Cleary, J. M., Wang, V., Heist, R. S., Kopetz, S., Mitchell, E. P., Zwiebel, J. A., Kapner, K. S., Chen, H. X., Li, S., Gray, R. J., et al. (2023) · doi:10.1158/1078-0432.c.6530100

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

Cleary, J. M., Wang, V., Heist, R. S., Kopetz, S., Mitchell, E. P., Zwiebel, J. A., Kapner, K. S., Chen, H. X., Li, S., Gray, R. J., et al. (2023) · doi:10.1158/1078-0432.c.6530100.v1

AI for Longevity: Getting Past the Mechanical Turk Model Will Take Good Data

Peshkin, L., & Kriukov, D. (2023) · Healthy ageing and longevity · doi:10.1007/978-3-031-35176-1_13

Computational precision therapeutics and drug repositioning

Powell, R. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00063-0

Personalized drug design: From models to therapeutics

Saleem, M. A. U., Abbas, G., Bano, F., Danish, M. A. U., Shehzad, M. S. U., Ali, M., Arain, M. H., Ullah, H., Khan, A., Bashir, T., et al. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33877-9.00003-3

Drug-Centric Prior Improves Drug Response Modeling in Partially Overlapping Pharmacogenomic Screens

Thirumalaisamy, D., Joshi, S. K., Kurtz, S. E., Vu, T. Q., Tyner, J. W., Gönen, M., & Nikolova, O. H. (2025) · Lecture notes in computer science · doi:10.1007/978-3-032-02489-3_13

Identification of genomic markers for drug sensitivity using Multi-task Learning

Aben, N. (2014) · Research Repository (Delft University of Technology)

Additional file 2 of Prevalence, causes and impact of TP53-loss phenocopying events in human tumors

Fito-Lopez, B., Salvadores, M., Alvarez, M.-M., & Supek, F. (2024) · Figshare · doi:10.6084/m9.figshare.26584569

Additional file 1 of Evaluation of statistical approaches for association testing in noisy drug screening data

Smirnov, P., Smith, I. C. P., Safikhani, Z., Ba-alawi, W., Khodakarami, F., Lin, E., Yu, Y., Martin, S. E., Ortmann, J., Aittokallio, T. A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19793292

Additional file 4 of Prevalence, causes and impact of TP53-loss phenocopying events in human tumors

Fito-Lopez, B., Salvadores, M., Alvarez, M.-M., & Supek, F. (2024) · Figshare · doi:10.6084/m9.figshare.26584575

Additional file 3 of Prevalence, causes and impact of TP53-loss phenocopying events in human tumors

Fito-Lopez, B., Salvadores, M., Alvarez, M.-M., & Supek, F. (2024) · Figshare · doi:10.6084/m9.figshare.26584572

Additional file 1 of QSAR-derived affinity fingerprints (part 2): modeling performance for potency prediction

Cortés‐Ciriano, I., Škuta, C., Bender, A., & Svozil, D. (2020) · Figshare · doi:10.6084/m9.figshare.12617895

Additional file 1 of Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer

Malik, V., Kalakoti, Y., & Sundar, D. (2021) · Figshare · doi:10.6084/m9.figshare.14299371

Additional file 1 of Prevalence, causes and impact of TP53-loss phenocopying events in human tumors

Fito-Lopez, B., Salvadores, M., Alvarez, M.-M., & Supek, F. (2024) · Figshare · doi:10.6084/m9.figshare.26584566

Genomics and proteomics in neurooncology

Elguindy, M. M., & Aghi, M. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00006-1

A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia

Lucas, C., Basabrain, A., Austin, G., Holcroft, A., Apperley, J. F., Clark, R. E., & Varadarajan, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072991

Applications of proteochemometrics (PCM) : from species extrapolation to cell-line sensitivity modelling

Cortés‐Ciriano, I. (2015) · theses.fr (ABES) · doi:10.70675/00fff70azab21z46edz8364z60031c95c00f

Caractérisation moléculaire et immunité des cancers du sein triple-négatifs

Bonsang‐Kitzis, H. (2018) · theses.fr (ABES) · doi:10.70675/285c912cz8251z4099z9cf7ze121cd7350d0

Pharmacogenomic and High-Throughput Data Analysis to Overcome Triple Negative Breast Cancers Drug Resistance

Sadacca, B. (2017) · theses.fr (ABES) · doi:10.70675/86d0b41azfb6bz44bdz9f35zf24452ba9c6a

Identification of Factors Predicting Sensitivity or Resistance to Neoadjuvant Chemotherapy in Breast Cancer

Hamy, A. (2019) · theses.fr (ABES) · doi:10.70675/77320e1az40e2z4404za739z3e0236f4e267

From 2D to 3D cell culture based in vitro test systems for glioblastoma anticancer drug screening

Harmouch, E. (2021) · theses.fr (ABES) · doi:10.70675/f8ad9a5ez2561z46d7z915ezdfdf7fecef48

Network-based machine learning methods to model variability across individuals

Yousefi, B. (2023) · theses.fr (ABES) · doi:10.70675/b7843ad7z3ae0z43caz9e47zf95945cd3b83

High-Throughput Screening Strategies in Microbial Studies

Sobti, R. C., & Khan, M. A. (2026) · Springer eBooks · doi:10.1007/978-981-95-8840-4_7

Pillbox: A Leakage-Aware Foundation-Model Predictor and Lineage-Ceiling Diagnostic for Cancer Drug ResponsePreprint

Hill, J., Jiao, E., Singh, S., Ghanta, A., Anders, D., Jeong, J. H., & Ryoo, H. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.08.725572

A tissue-aware computational framework for confounding-controlled co-expression network analysis: Context-dependent utility in drug sensitivity modelling

Cadenas, M. R., Segura-Carmona, I., López, A. L., & Gómez-Vela, F. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109235

DDI-MMAF: Multi-modal affine fusion of visual and semantic representations for anticancer drug synergy prediction

Li, H., Jiang, Q., Guan, J., He, X., Xie, P., Zhao, Z., Liu, X., Liu, X., Lee, T.-Y., Wei, L., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119134

Textural features for pathway-level representation of omics data in biological networksPreprint

Alexeyenko, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.12.737672

CellGPT Map: A Universal Causal Embedding Atlas of Cancer Cells Revealing Therapeutic Similarity beyond Anatomical Origin Article type: Hypothesis and Theory (Perspective)Preprint

Ahmed, A. K. K., & almutairi, K. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7216082

Separating drug main effects from molecular personalization in cancer drug-sensitivity prediction: a harmonized GDSC∪CTRP and CCLE benchmark with permutation-controlled biomarker discoveryPreprint

Hao, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-10579394/v1

BiDRA: Bayesian inference as a robust alternative to non-linear regression for dose–response efficiency metrics assessment

Labelle, C., Smirnov, P., David, M., Callejo, M., Haibe‐Kains, B., Marinier, A., & Lemieux, S. (2026) · Bioinformatics Advances · doi:10.1093/bioadv/vbag245

PKIDB-informed molecular profiling improves reproducible prediction of cancer kinase-inhibitor response

Liu, M., Song, J., Liu, X., Zhao, L., & Xiong, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1923164

ORGANOIDS IN CANCER RESEARCH: EXPANDING THE SCOPE OF PRECISION ONCOLOGY”

Bose, G. S., Kumari, R., Reur, P. N., Mittal, S. P. K., Kulkarni, A. P., Bhosale, S., Aggarwal, S., Agarwal, P., Agarwal, P., & Datkhile, K. D. (2026) · Acta Innovations · doi:10.62441/actainnovations.v63i1s.1644

A Multi-Kinase Inhibitor Screen Identifies mTOR Signaling as a Vulnerability in Advanced Prostate CancerPreprint

Sridhar, S., Mohan, K., Kizhake, S., Natarajan, A., Kelly, D. L., & Mathew, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.13.758818

Artificial intelligence in cancer transcriptomics: methods, applications in oncology, and limitations

Solovev, I. A., & Golubev, D. (2026) · Pharmacokinetics and Pharmacodynamics · doi:10.37489/2587-7836-2026-3-84-94

Drug and toxicity screening using multitissue systems

Jayaseelan, M. M., & Skardal, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-16110-0.00033-9

Transcriptomic similarity guides source selection beyond tissue lineagePreprint

Jiang, L., Pang, J., Luo, B., Wu, X., Li, X., & Zhang, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.26.761823

Discrepancies in drug sensitivity

Weinstein, J. N., & Lorenzi, P. L. (2013) · Nature · doi:10.1038/nature12839 · Cited by 42

Revisiting inconsistency in large pharmacogenomic studies

Safikhani, Z., Smirnov, P., Freeman, M., El-Hachem, N., She, A., Rene, Q., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L. M., et al. (2017) · F1000Research · doi:10.12688/f1000research.9611.2 · Cited by 8

Consistency in drug response profiling

Mpindi, J. P., Yadav, B., Östling, P., Gautam, P., Malani, D., Murumägi, A., Hirasawa, A., Kangaspeska, S., Wennerberg, K., Kallioniemi, O., et al. (2016) · Nature · doi:10.1038/nature20171 · Cited by 85

Safikhani et al. reply

Safikhani, Z., El-Hachem, N., Smirnov, P., Freeman, M., Goldenberg, A., Birkbak, N. J., Beck, A. H., Aerts, H. J. W. L., Quackenbush, J. F., & Haibe‐Kains, B. (2016) · Nature · doi:10.1038/nature20172 · Cited by 9

Pharmacogenomic agreement between two cancer cell line data sets

The Cancer Cell Line Encyclopedia Consortium, & The Genomics of Drug Sensitivity in Cancer Consortium (2015) · Nature · doi:10.1038/nature15736 · Cited by 418